文献速递银屑病与炎症性皮肤病皮肤肿瘤

参与临床试验的中重度银屑病患者全身氟脱氧葡萄糖F18正电子发射断层扫描/计算机断层扫描扫描中具有临床意义的偶发发现患病率

Prevalence of clinically significant incidental findings by whole-body fludeoxyglucose F 18 positron emission tomography/computed tomography scanning in moderate-to-severe psoriasis patients participating in clinical trials.
PubMed 文献 · J Am Acad Dermatol · 2019-01-14

该研究为3项关于银屑病血管炎症的4期临床试验的横断面二次分析,纳入259例无活动性感染、恶性肿瘤或未控制合并症的中重度银屑病患者,在基线随机化前接受FDG PET/CT扫描。31例(11.97%,95%CI 8.28-16.56)存在具有临床意义的偶发瘤;年龄每增加10岁,发现偶发瘤的风险约增加30%(OR 1.30,95%CI 1.01-1.68)。28例提示恶性肿瘤的患者中6例确诊癌症,恶性肿瘤患病率为2.31%(95%CI 0.9-5.0),真癌阳性预测值为31.58%(范围21%-54%)。

要点

  • 中重度银屑病临床试验患者中,基线FDG PET/CT偶发瘤患病率为11.97%(95%CI 8.28-16.56)。
  • 年龄每增加10岁,偶发瘤发现风险约增加30%(OR 1.30,95%CI 1.01-1.68)。
  • 提示恶性肿瘤者中真癌阳性预测值为31.58%(范围21%-54%),恶性肿瘤患病率2.31%(95%CI 0.9-5.0)。

核心结论

  • 在临床试验中,看似健康、无症状的中重度银屑病患者FDG PET/CT偶发瘤常见。
  • 研究结果有助于解读临床试验安全性数据,并强调遵循癌症筛查推荐的重要性。

研究设计与样本

  • 横断面二次分析,纳入3项关于银屑病血管炎症的4期临床试验中在基线访视、随机化前接受FDG PET/CT扫描的中重度银屑病患者。
  • 仅无活动性感染、恶性肿瘤或未控制合并症的患者符合临床试验入选条件。
  • 共259例健康的中重度银屑病患者接受了FDG PET/CT扫描作为研究程序的一部分。

主要发现

  • 31例患者(11.97%,95%CI 8.28-16.56)在基线FDG PET/CT扫描中发现具有临床意义的偶发瘤。
  • 单变量逻辑回归显示,年龄每增加10岁,发现偶发瘤的风险约增加30%(OR 1.30,95%CI 1.01-1.68)。
  • 28例患者发现提示恶性肿瘤的征象,其中6例确诊癌症,恶性肿瘤患病率为2.31%(95%CI 0.9-5.0)。
  • 真癌阳性预测值为31.58%(范围21%-54%)。

局限性

  • 原文报告的局限性包括普遍性(generalizability)和失访(lost to follow-up)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There has been an increase in the number of psoriasis treatments being investigated in clinical trials. Patients may have undiagnosed issues at the start of a study which may become identified during follow-up as incident medicinal conditions. The prevalence of incidental findings in patients with moderate-to-severe psoriasis presenting for clinical trials is unknown. OBJECTIVE: Determine the prevalence of incidentalomas and rate of malignancy identified by fludeoxyglucose F 18 (FDG) positron emission tomography/computed tomography (PET/CT) imaging in clinical trial patients with moderate-to-severe psoriasis. METHODS: A cross-sectional secondary analysis of patients with moderate-to-severe psoriasis who underwent FDG PET/CT scans at the baseline visit, before randomization, for 3 phase 4 clinical trials on vascular inflammation in psoriasis. Only patients without active infection, malignancy, or uncontrolled comorbidities were eligible for the clinical trials. RESULTS: A total of 259 healthy patients with moderate-to-severe psoriasis underwent an FDG PET/CT scan as part of the study procedures. In all, 31 patients (11.97%) (95% confidence interval [CI], 8.28-16.56) had clinically significant incidentalomas on the baseline FDG PET/CT scan. Univariate logistic regression demonstrated that with every increase of 10 years of age, there was an approximate 30% increased risk of discovery of an incidentaloma (odds ratio, 1.30; 95% CI, 1.01-1.68). Of those patients with findings suggestive of malignancy (n = 28), 6 were confirmed to have cancer, resulting in a 2.31% (95% CI, 0.9-5.0) prevalence of malignancy. The positive predictive value of a true cancer was 31.58% (range, 21%-54%). LIMITATIONS: Generalizability and lost to follow-up. CONCLUSION: Incidentalomas on FDG PET/CT imaging are common in otherwise healthy, asymptomatic patients with moderate-to-severe psoriasis in clinical trials. Our results can help inform interpretation of clinical trial safety data and emphasize the importance of compliance with cancer screening recommendations.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Wan MT, Torigian DA, Alavi A, et al. Prevalence of clinically significant incidental findings by whole-body fludeoxyglucose F 18 positron emission tomography/computed tomography scanning in moderate-to-severe psoriasis patients participating in clinical trials. J Am Acad Dermatol. 2019. PMID: 30654078. doi:10.1016/j.jaad.2019.01.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。